Amidst geopolitical uncertainty, healthcare remains a unifying priority across different regions.
Patients, providers and industry all, ultimately, share the same goal: access to high-quality, effective therapies that improve patient outcomes and drive efficiencies in healthcare management.
For US biotech companies, tariffs and geopolitics may dominate the headlines, but they are forging ahead with strategic investments and partnerships across the Asia-Pacific region (APAC) and the Middle East.
However, it is a tricky market to navigate, with each country having its own unique timelines, documentation requirements and clinical infrastructure.
Therefore, a standardised approach to regulatory frameworks is ineffective.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.